GSK has agreed to acquire U.S. biotech firm Nuvalent in a $10.6 billion all-cash transaction, marking its biggest acquisition in more than ten years and a decisive push to strengthen its oncology portfolio, particularly in lung cancer treatments.
The deal, confirmed in a filing on Tuesday and first reported by the Financial Times, values Nuvalent at about $124 per share, a 40% premium to its previous closing price. It represents the second-largest acquisition in GSK’s corporate history, trailing only its 2014 asset swap with Novartis that reshaped its vaccines business.
The transaction marks a shift under new chief executive Luke Miels, who has moved away from the company’s recent preference for smaller, incremental acquisitions toward larger, pipeline-defining deals aimed at restoring long-term revenue growth.
Register for Tekedia Mini-MBA edition 20 (June 8 – Sept 5, 2026).
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Register for Tekedia AI Lab.
With this deal, the oncology pipeline appears to become central to GSK’s strategy. At the core of the acquisition is Nuvalent’s experimental lung cancer portfolio, which GSK views as a platform for expanding its oncology franchise.
Nuvalent’s lead candidate, neladalkib, is currently under review by the U.S. Food and Drug Administration, with a decision expected by November 27. The therapy targets specific genetic mutations associated with non-small cell lung cancer, one of the largest oncology markets globally.
The company also has zidesamtinib under regulatory review, another targeted therapy aimed at ROS1-positive non-small cell lung cancer patients.
GSK has positioned the acquisition as a near-term revenue catalyst as well as a longer-term growth engine. The company expects the deal to begin contributing to revenue growth from 2027, with Improvements in profit contribution also expected from that year onward. Importantly, GSK has maintained its 2026 guidance for core operating profit and earnings-per-share growth, signaling that integration costs are expected to remain contained in the near term.
Industry Pressure From Patent Cliffs Drives Consolidation
The acquisition comes amid a broader wave of pharmaceutical dealmaking, as large drugmakers race to replace revenue streams threatened by expiring drug patents and slowing growth in legacy franchises.
Global biotech and pharmaceutical deal value has surged in 2026, with transactions reaching $106 billion across more than 200 deals, according to PitchBook data. The sector is on track for its strongest year since the pre-pandemic peak, driven by a combination of investor optimism, improved financing conditions, and intensified competition for late-stage drug assets.
Lung cancer remains one of the most lucrative therapeutic areas in oncology due to its high prevalence, complex biology, and continued demand for targeted therapies. That has made it a focal point for pharmaceutical companies seeking to secure differentiated assets with regulatory traction.
The deal also reflects a recalibration of GSK’s capital allocation strategy. Under previous guidance, the company had emphasized smaller transactions in the £2 billion to £4 billion range. Miels had previously described attractive opportunities in that range as “hiding in plain sight,” signaling a cautious approach to large-scale mergers.
The Nuvalent acquisition suggests a shift toward more aggressive portfolio rebuilding, particularly in high-value therapeutic categories such as oncology and immunology. Nuvalent itself has emerged as a high-profile clinical-stage biotech, with investor attention driven by its targeted approach to genetically defined cancers. Analysts have estimated that its lead therapies could generate combined annual revenues of roughly $823 million by 2029 if approved and successfully commercialized.
The transaction adds to a broader consolidation in the biotech sector, where large pharmaceutical firms are increasingly absorbing mid-sized innovation companies rather than developing late-stage drug candidates in-house. Rising research costs, longer development timelines, and regulatory uncertainty have pushed big pharma toward external innovation pipelines.
At the same time, improved capital market conditions have made biotech assets more expensive, intensifying competition among buyers.
The deal is thus both defensive and offensive for GSK: it mitigates pipeline risk while positioning the company in a competitive oncology segment where rival pharmaceutical groups are also expanding aggressively. The integration is expected to give GSK a more immediate foothold in precision oncology and potentially reshape its long-term revenue profile.